Methods Of Making Chimeric Antigen Receptor -Expressing Cells - EP3397755

The patent EP3397755 was granted to Novartis on Nov 6, 2024. The application was originally filed on Dec 27, 2016 under application number EP16829368A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3397755

NOVARTIS
Application Number
EP16829368A
Filing Date
Dec 27, 2016
Status
Granted And Under Opposition
Oct 3, 2024
Grant Date
Nov 6, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANAug 1, 2025HASELTINE LAKE KEMPNER -

Patent Citations (68) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0090505
DESCRIPTIONEP1866339
DESCRIPTIONEP1947183
DESCRIPTIONUS2004101519
DESCRIPTIONUS2006034810
DESCRIPTIONUS2006121005
DESCRIPTIONUS5350674
DESCRIPTIONUS5585362
DESCRIPTIONUS5786464
DESCRIPTIONUS5858358
DESCRIPTIONUS5883223
DESCRIPTIONUS6111090
DESCRIPTIONUS6114148
DESCRIPTIONUS6326193
DESCRIPTIONUS6352694
DESCRIPTIONUS6534055
DESCRIPTIONUS6692964
DESCRIPTIONUS6703199
DESCRIPTIONUS6797514
DESCRIPTIONUS6867041
DESCRIPTIONUS6887466
DESCRIPTIONUS6905680
DESCRIPTIONUS6905681
DESCRIPTIONUS6905874
DESCRIPTIONUS7025962
DESCRIPTIONUS7067318
DESCRIPTIONUS7144575
DESCRIPTIONUS7172869
DESCRIPTIONUS7175843
DESCRIPTIONUS7232566
DESCRIPTIONUS7446190
DESCRIPTIONUS7618632
DESCRIPTIONUS7812135
DESCRIPTIONUS8388967
DESCRIPTIONUS8399645
DESCRIPTIONUS8586023
DESCRIPTIONUS8591886
DESCRIPTIONUS8664194
DESCRIPTIONUS8680069
DESCRIPTIONUS8710200
DESCRIPTIONUS8754062
DESCRIPTIONUS8822663
DESCRIPTIONWO0103720
DESCRIPTIONWO0129058
DESCRIPTIONWO0196584
DESCRIPTIONWO03014161
DESCRIPTIONWO2005007190
DESCRIPTIONWO2005055808
DESCRIPTIONWO2005115451
DESCRIPTIONWO2006083289
DESCRIPTIONWO2007133822
DESCRIPTIONWO2010003118
DESCRIPTIONWO2011028683
DESCRIPTIONWO2011051726
DESCRIPTIONWO2011056894
DESCRIPTIONWO2011090754
DESCRIPTIONWO2013039954
DESCRIPTIONWO2013126712
DESCRIPTIONWO2014055442
DESCRIPTIONWO2014055657
DESCRIPTIONWO9404678
DESCRIPTIONWO9920758
DESCRIPTIONWO9940196
INTERNATIONAL-SEARCH-REPORTCN105158466
INTERNATIONAL-SEARCH-REPORTWO2015164745
OPPOSITIONWO2014153270
OPPOSITIONWO2015164745
OTHERWO2015164745

Non-Patent Literature (NPL) Citations (104) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AGATA ET AL., INT. IMMUNOL, (1996), vol. 8, pages 765 - 775-
DESCRIPTION- AGGEN ET AL., GENE THER., (201204), vol. 19, no. 4, pages 365 - 374-
DESCRIPTION- AGGEN ET AL., GENE THER., (2012), vol. 19, no. 4, pages 365 - 374-
DESCRIPTION- AL-LAZIKANI ET AL., JMB, (1997), vol. 273, pages 927 - 948-
DESCRIPTION- ARONOVICH ET AL., HUM. MOL. GENET., (2011), vol. 20.R1, pages R14 - R20-
DESCRIPTION- BATZER ET AL., NUCLEIC ACID RES., (1991), vol. 19, page 5081-
DESCRIPTION- BELL ET AL., NAT. PROTOC., (2007), vol. 2.12, pages 3153 - 3165-
DESCRIPTION- BERG ET AL., TRANSPLANT PROC., (1998), vol. 30, no. 8, pages 3975 - 3977-
DESCRIPTION- BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426-
DESCRIPTION- BLANK ET AL., CANCER IMMUNOL. IMMUNOTHER, (2005), vol. 54, pages 307 - 314-
DESCRIPTION- BRENTJENS ET AL., BLOOD, (2011), vol. 118, no. 18, pages 4817 - 4828-
DESCRIPTION- CARL JUNE, "Adoptive T cell therapy for cancer in the clinic", JOURNAL OF CLINICAL INVESTIGATION, (2007), vol. 117, pages 1466 - 1476-
DESCRIPTION- CARTER ET AL., EUR J IMMUNOL, (2002), vol. 32, pages 634 - 643-
DESCRIPTION- COUGOT ET AL., TRENDS IN BIOCHEM. SCI., (2001), vol. 29, pages 436 - 444-
DESCRIPTION- CRADDOCK ET AL., J IMMUNOTHER., (201010), vol. 33, no. 8, pages 780 - 788-
DESCRIPTION- CRUZ ET AL., BLOOD, (2013), vol. 122.17, pages 2965 - 2973-
DESCRIPTION- CRUZ ET AL., BLOOD, (2013), vol. 122, no. 17, pages 2965 - 2973-
DESCRIPTION- DAO ET AL., SCI TRANSL MED, (2013), vol. 5, no. 176, page 176RA33-
DESCRIPTION- DING ET AL., CELL, (2005), vol. 122.3, pages 473 - 483-
DESCRIPTION- DI STASA ET AL., N ENGL. J. MED., (20111103), vol. 365, no. 18, pages 1673 - 1683-
DESCRIPTION- DI STASI ET AL., N. ENGL. J. MED., (2011), vol. 365, pages 1673 - 1683-
DESCRIPTION- DONG ET AL., J MOL MED, (2003), vol. 81, pages 281 - 287-
DESCRIPTION- ELANGO ET AL., BIOCHIM. BIOPHYS. RES. COMMUN., (2005), vol. 330, pages 958 - 966-
DESCRIPTION- FREEMAN, J EXP MED, (2000), vol. 192, pages 1027 - 1034-
DESCRIPTION- GARLAND ET AL., J. IMMUNOL METH., (1999), vol. 227, no. 1-2, pages 53 - 63-
DESCRIPTION- GHOSH ET AL., GLYCOBIOLOGY, (1991), vol. 5, pages 505 - 510-
DESCRIPTION- GRABUNDZIJA ET AL., MOL. THER., (2010), vol. 18, pages 1200 - 1209-
DESCRIPTION- GRABUNDZIJA ET AL., NUCLEIC ACIDS RES., (2013), vol. 41.3, pages 1829 - 1847-
DESCRIPTION- HAANEN ET AL., J. EXP. MED., (1999), vol. 190, no. 9, pages 1319 - 1328-
DESCRIPTION- HAMERS-CASTERMAN, C. ET AL., NATURE, (1993), vol. 363, pages 446 - 448-
DESCRIPTION- HOLLINGER ET AL., PROC NATL ACAD. SCI. U.S.A., (1993), vol. 90, pages 6444 - 6448-
DESCRIPTION- HOLLINGER; HUDSON, NATURE BIOTECHNOLOGY, (2005), vol. 23, pages 1126 - 1136-
DESCRIPTION- HOUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883-
DESCRIPTION- HUANG ET AL., MOL. THER., (2008), vol. 16, pages 580 - 589-
DESCRIPTION- HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883-
DESCRIPTION- JENA ET AL., "Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T cells in Clinical Trials", PLOS, (20130308), vol. 3, page E57838-
DESCRIPTION- JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525-
DESCRIPTION- JONNALAGADDA ET AL., GENE THER., (2013), vol. 20, no. 8, pages 853 - 860-
DESCRIPTION- JUNE ET AL., NATURE REVIEWS IMMUNOLOGY, (2009), vol. 9.10, pages 704 - 716-
DESCRIPTION- KEBRIAEI ET AL., BLOOD, (2013), vol. 122.21, page 166-
DESCRIPTION- KERSHAW ET AL., HUM GENE THER., (20021101), vol. 13, no. 16, pages 1971 - 1980-
DESCRIPTION- KOCHENDERFER ET AL., BLOOD, (2010), vol. 116, no. 20, pages 4099 - 4102-
DESCRIPTION- KOCHENDERFER ET AL., BLOOD, (2013), vol. 122.25, pages 4129 - 4139-
DESCRIPTION- KOCHENDERFER ET AL., BLOOD, (2013), vol. 122, no. 25, pages 4129 - 4139-
DESCRIPTION- KONISHI ET AL., CLIN CANCER RES, (2004), vol. 10, page 5094-
DESCRIPTION- LANZAVECCHIA ET AL., EUR. J. IMMUNOL., (1987), vol. 17, page 105-
DESCRIPTION- LATCHMAN ET AL., NAT IMMUNOL, (2001), vol. 2, pages 261 - 268-
DESCRIPTION- MEYERSON ET AL., "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization", CELL, (19970822), vol. 90, no. 4, pages 785 - 795-
DESCRIPTION- MILONE ET AL., MOLECULAR THERAPY, (2009), vol. 17, no. 8, pages 1453 - 1464-
DESCRIPTION- MILONE ET AL., MOL. THER., (2009), vol. 17, no. 8, pages 1453 - 1464-
DESCRIPTION- NACHEVA; BERZAL-HERRANZ, EUR. J. BIOCHEM., (2003), vol. 270, pages 1485 - 1465-
DESCRIPTION- NISHIKAWA ET AL., HUM GENE THER., (2001), vol. 12, no. 8, pages 861 - 870-
DESCRIPTION- OHTSUKA ET AL., J. BIOL. CHEM., (1985), vol. 260, pages 2605 - 2608-
DESCRIPTION- PHILIP ET AL., BLOOD, (2014), vol. 124, no. 8, pages 1277 - 1287-
DESCRIPTION- PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596-
DESCRIPTION- REICHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329-
DESCRIPTION- ROSENBERG ET AL., NEW ENG. J. OF MED., (1988), vol. 319, page 1676-
DESCRIPTION- ROSSOLINI ET AL., MOL. CELL. PROBES, (1994), vol. 8, pages 91 - 98-
DESCRIPTION- ROTH ET AL., "Significantly shorter telomeres in T-cells of patients with ZAP-70+/CD38 chronic lymphocytic leukaemia", BRITISH JOURNAL OF HAEMATOLOGY, (20080828), vol. 143, pages 383 - 386-
DESCRIPTION- SAMBROOK ET AL., MOLECULAR CLONING: A LABORATORY MANUAL, COLD SPRING HARBOR PRESS, (2012), vol. 1-4-
DESCRIPTION- SASTRY ET AL., J VIROL., (2011), vol. 85, no. 5, pages 1935 - 1942-
DESCRIPTION- SCHENBORN; MIERENDORF, NUC ACIDS RES., (1985), vol. 13, pages 6223 - 6236-
DESCRIPTION- SERGEEVA ET AL., BLOOD, (2011), vol. 117, no. 16, pages 4262 - 4272-
DESCRIPTION- SINGH ET AL., CANCER RES., (2008), vol. 15, pages 2961 - 2971-
DESCRIPTION- SINGH ET AL., CANCER RES., (2008), vol. 68.8, pages 2961 - 2971-
DESCRIPTION- SMITH ET AL., "Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement", CLINICAL & TRANSLATIONAL IMMUNOLOGY, (2015), vol. 4, page E31-
DESCRIPTION- SONG ET AL., BLOOD, (2012), vol. 119, no. 3, pages 696 - 706-
DESCRIPTION- SONG ET AL., CANCER GENE THER., (2008), vol. 15, no. 10, pages 667 - 675-
DESCRIPTION- STEPINSKI ET AL., RNA, (2001), vol. 7, pages 1468 - 1495-
DESCRIPTION- STRELTSOV, PROTEIN SCI., (2005), vol. 14, pages 2901 - 2909-
DESCRIPTION- TASSEV ET AL., CANCER GENE THER, (2012), vol. 19, no. 2, pages 84 - 100-
DESCRIPTION- TOBIAS MAETZIG ET AL., "Gammaretroviral Vectors: Biology, Technology and Application", VIRUSES, (201106), vol. 3, no. 6, pages 677 - 713-
DESCRIPTION- UI-TEI ET AL., FEBS LETTERS, (2000), vol. 479, pages 79 - 82-
DESCRIPTION- VERMA ET AL., J IMMUNOL, (2010), vol. 184, no. 4, pages 2156 - 2165-
DESCRIPTION- WILLEMSEN ET AL., GENE THER, (2001), vol. 8, no. 21, pages 1601 - 1608-
DESCRIPTION- WILLEMSEN RA ET AL., GENE THERAPY, (2000), vol. 7, pages 1369 - 1377-
DESCRIPTION- WILLIAMS, MOLECULAR THERAPY, (2008), vol. 16.9, pages 1515 - 1516-
DESCRIPTION- XU ET AL., BLOOD, (2014), vol. 123.24, pages 3750 - 3759-
DESCRIPTION- XU ET AL., LEUK LYMPHOMA, (2012), vol. 54, no. 2, pages 255 - 260-
DESCRIPTION- ZHANG T ET AL., CANCER GENE THER, (2004), vol. 11, pages 487 - 496-
EXAMINATION- DAVID F STRONCEK ET AL, "Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, (20140917), vol. 12, no. 1, doi:10.1186/S12967-014-0241-Y, ISSN 1479-5876, page 241, XP021198581
INTERNATIONAL-SEARCH-REPORT- SAUL J. PRICEMAN ET AL, "Smart CARs engineered for cancer immunotherapy", CURRENT OPINION IN ONCOLOGY, GB, (20151101), vol. 27, no. 6, doi:10.1097/CCO.0000000000000232, ISSN 1040-8746, pages 466 - 474, XP055359846 [Y] 1-11,46-53,57-60 * page 4, paragraph 2 *
INTERNATIONAL-SEARCH-REPORT- Tengfei Zhang ET AL, "Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis", Oncotarget, United States, (20151020), page 33961, URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741817/pdf/oncotarget-06-33961.pdf, XP055359845 [Y] 1-11,46-53,57-60 * page 33962, column 1, paragraph 2 *
OPPOSITION- Anonymous, "Optimizing Cell Separation with Beckman Coulter's Centrifugal Elutriation System", BECKMAN COULTER Life Sciences, (20140101), XP093304638-
OPPOSITION- Dorin Mel, "Developing Elutriation Protocols (T-1785A)", BECKMAN, (19940101), XP093304639-
OPPOSITION- Pujari Amit, Man Chi-Wei, Park Jinsang, Wattenbarger Miriam, Levine Bruce, , "T-cell manufacture for treatment of acute lymphoblastic leukemia", Report, University of Pennsylvania, (20150414), Report, University of Pennsylvania, URL: https://repository.upenn.edu/bitstreams/b9f49e83-a13f-4418-82cd-ab62f4dbc642/download, XP093304634-
OPPOSITION- Grupp et al, "Advances in T-cell therapy for ALL", Best Practice & Research Clinical Haematology , (2014), vol. 27, no. 3-4, doi:10.1016/j.beha.2014.10.014, pages 222 - 228, XP055970588
OPPOSITION- Lemarie et al, "Purification of monocytes from cryopreserved mobilized apheresis products by elutriation with the Elutra device", Journal of Immunological Methods, (20070110), vol. 318, doi:10.1016/j.jim.2006.07.028, XP005820133
OPPOSITION- Themeli et al, "New Cell Sources for T Cell Engineering and Adoptive Immunotherapy", Cell Stem Cell, (20150402), vol. 16, doi:10.1016/j.stem.2015.03.011, XP093154105
OPPOSITION- Kaiser et al, "Towards a commercial process for the manufacture of genetically modified T cells for therapy", Cancer Gene Therapy, (20150123), vol. 22, doi:10.1038/cgt.2014.78, pages 72 - 78, XP055211554
OPPOSITION- Levine, "Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells", Cancer Gene Therapy, (20150213), vol. 22, doi:10.1038/cgt.2015.5, XP037761808
OPPOSITION- Banfalvi Gaspar, "Cell cycle synchronization of animal cells and nuclei by centrifugal elutriation", Nature Protocols, Nature Publishing Group, GB, GB , (20080401), vol. 3, no. 4, doi:10.1038/nprot.2008.34, ISSN 1754-2189, pages 663 - 673, XP093304631
OPPOSITION- Gomez-Eerland Raquel, Nuijen Bastiaan, Heemskerk Bianca, Van Rooij Nienke, Van Den Berg Joost H., Beijnen Jos H., Uckert Wolfgang, Kvistborg Pia, Schumacher Ton N., Haanen John B.A.G., Jorritsma Annelies, "Manufacture of Gene-Modified Human T-Cells with a Memory Stem/Central Memory Phenotype", Human Gene Therapy, Springer, US, US , (20141001), vol. 25, no. 5, doi:10.1089/hgtb.2014.004, ISSN 1946-6536, pages 277 - 287, XP093304623
OPPOSITION- Maier et al, "Efficient Clinical Scale Gene Modification via Zinc Finger Nuclease-Targeted Disruption of the HIV Co-receptor CCR5", Human Gene Therapy, (201303), vol. 24, doi:10.1089/hum.2012.172, XP055542499
OPPOSITION- Hollyman et al, "Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy", Journal of Immunotherapy, (2009), vol. 32, doi:10.1097/CJI.0b013e318194a6e8, XP093131401
OPPOSITION- Fisher Virginia, Khuu Hanh, David‐ocampo Virginia, Byrne Karen, Pavletic Steven, Bishop Michael, Fowler Daniel H., Barrett A. John, Stroncek David F., "3+ cells collected for hematopoietic transplantation", Transfusion, AMERICAN ASSOCIATION OF BLOOD BANKS, BETHESDA, MD., US, US , (20140401), vol. 54, no. 4, doi:10.1111/trf.12428, ISSN 0041-1132, pages 1088 - 1092, XP093304626
OPPOSITION- Kalos et al, "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", Sci. Transl Med. , (20110810), vol. 3, doi:10.1126/scitranslmed.3002842, page 95, XP002667262
OPPOSITION- Rapoport Aaron P., Aqui Nicole A., Stadtmauer Edward A., Vogl Dan T., Xu Yin Yan, Kalos Michael, Cai Ling, Fang Hong-Bin, Weiss Brendan M., Badros Ashraf, Yanovich Saul, Akpek Gorgun, Tsao Patricia, Cross Alan, Mann Dean, Philip Sunita, Kerr Naseem, Brennan Andrea, Zheng Zhaohui, Ruehle Kathleen, Milliron Todd, Strome Scott E., Salazar Andres M., Levine Bruce L., June Carl H., "Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells", Clinical cancer research, American Association for Cancer Research Inc, (20140301), vol. 20, no. 5, doi:10.1158/1078-0432.CCR-13-2817, ISSN 1078-0432, pages 1355 - 1365, XP093304629
OPPOSITION- Boyd et al, "Successful Translation of Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Cell Processing Technology from Academia to Industry", Blood, (20151203), vol. 126, no. 23, doi:10.1182/blood.V126.23.3100.3100, page 3100, XP086645015
OPPOSITION- Eastwood et al, "Cryopreserved leukopaks maintain cell viability and functionality:A solution for cell therapy logistics", Journal for ImmunoTherapy of Cancer, (20151104), vol. 3, doi:10.1186/2051-1426-3-S2-P383, XP021235550
OPPOSITION- Stroncek et al, "Counter-flow elutriation of clinical peripheral blood mononuclear cell concentrates for the production of dendritic and T cell therapies", Journal of Translational Medicine, (20140917), vol. 12, doi:10.1186/s12967-014-0241-y, XP021198581
OPPOSITION- Mythili Koneru, Roisin O’cearbhaill, Swati Pendharkar, David R Spriggs, Renier J Brentjens, "A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16ecto directed chimeric antigen receptors for recurrent ovarian cancer", Journal of Translational Medicine, BioMed Central Ltd, (20151228), vol. 13, no. 1, doi:10.1186/s12967-015-0460-x, XP055469378
OPPOSITION- Daniel J. Powell Jr, Andrea L. Brennan, Zhaohui Zheng, Hong Huynh, Julio Cotte, Bruce L. Levine, "Efficient clinical-scale enrichment of lymphocytes for use in adoptive immunotherapy using a modified counterflow centrifugal elutriation program", Cytotherapy, ISIS MEDICAL MEDIA, OXFORD,, GB, GB , (20091110), vol. 11, no. 7, doi:10.3109/14653240903188921, ISSN 1465-3249, pages 923 - 935, XP009562840
OPPOSITION- Smith Barry C., Persson Agneta, Wikfors Gary H., "A particle separator used to concentrate Dinoflagellate cysts from sediment", Limnology and Oceanography: Methods, American Society of Limnology and Oceanography, Inc., US, US , (20090701), vol. 7, no. 7, doi:10.4319/lom.2009.7.521, ISSN 1541-5856, pages 521 - 526, XP093304632

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents